Search clinical trials for: Cyclin-Dependent Kinase Inhibitor Proteins

Total 11753 results

Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States, Canada, Australia, Puerto Rico
Roswell Park Cancer Institute
National Cancer Institute (NCI); Boehringer Ingelheim

Completed

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation; H. Jean Khoury Cure CML Consortium

Recruiting

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

Chronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid Leukemia

United States
PrECOG, LLC.
Pfizer

Terminated

NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801)

Renal Cell Carcinoma

United States
Loxo Oncology, Inc.

Available

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Lymphoma, Mantle-Cell | Waldenstrom Macroglobulinemia | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, Lymphocytic, Small | Ritcher's Transformation, Syndrome
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Recurrent Pleural Malignant Mesothelioma | Stage IV Pleural Mesothelioma

United States
RenJi Hospital

Recruiting

Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC

Hepatocellular Carcinoma | Liver Cancer | Resistant Cancer

China
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Active, not recruiting

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Melanoma | Unresectable Melanoma | Advanced Melanoma

United States
Pfizer

Recruiting

Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis (TOFAST)

Ulcerative Colitis

France
Bangabandhu Sheikh Mujib Medical University, Dhaka...
Incepta Pharmaceuticals Ltd

Completed

Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study

Axial Spondyloarthritis

Bangladesh
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm

United States
Albany Research Institute, Inc.

Completed

Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea (TOMIR)

Rosacea, Erythematotelangiectatic

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Completed

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Carcinoid Tumor | Neuroendocrine Neoplasm | Metastatic Carcinoid Tumor

United States
University Hospital, Lille
Pfizer

Terminated

Effects of Tofacitinib on Body Composition, Bone Mineral Density and Bone Marrow Adiposity in Patients With Rheumatoid Arthritis: the TOFAT Project (TOFAT)

Rheumatoid Arthritis

France
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Northwestern University
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Active, not recruiting

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia | Hairy Cell Leukemia Variant

United States
Jinnah Hospital

Completed

Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

Pakistan
Pfizer

Completed

Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis (ESCALATE-RA)

Arthritis, Rheumatoid

Germany
Hoffmann-La Roche

Active, not recruiting

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Hungary, Australia, Taiwan, China, Denmark, Italy, Spain, Turkey, Japan, France, Korea, Republic of, Germany, Poland, Thailand, Egypt, Russian Federation, Austria, Ukraine, United Kingdom, Romania, Kazakhstan, Bosnia... and more
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Fudan University

Active, not recruiting

Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer

Thyroid Cancer

China
Pfizer

Recruiting

Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden (ODEN)

Ulcerative Colitis

Sweden
Boehringer Ingelheim

Completed

Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer

Breast Neoplasms

United States, Australia, Hong Kong, Korea, Republic of, Thailand, Tunisia, United Kingdom
National Cancer Institute (NCI)

Recruiting

Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

Gynecologic Cancer | Colorectal Neoplasms | Colorectal Cancer | Ovarian Neoplasms | Peritoneal Neoplasms | Ovarian Cancer | Peritoneal Carcinomatosis | Appendiceal Neoplasms | Appendiceal Cancer | Gynecologic Neoplasms

United States
Children's Hospital Medical Center, Cincinnati
Pfizer

Completed

Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

Systemic Lupus Erythematosus | Cutaneous Lupus

United States
National Cancer Institute (NCI)

Active, not recruiting

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Soft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma | Malignant Glioma | Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma and other conditions

United States, Puerto Rico
Sahar Mohammed Gad

Not yet recruiting

Chronic Kidney Disease Patient in Chronic Myloied Leukemia

Chronic Myeloid Leukemia in Remission
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

Hematopoietic and Lymphoid Cell Neoplasm | Steroid Refractory Graft Versus Host Disease

United States
Zhejiang Provincial People's Hospital

Recruiting

Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

Rheumatoid Arthritis | Treatment Compliance | Abatacept

China
Pfizer

Recruiting

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Israel, Poland, Canada, Japan, Belgium, Spain, Hungary, Finland, France, United Kingdom, Australia, Germany, Italy, Sweden, Netherlands, Slovakia
Pfizer

Completed

IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis

Arthritis, Rheumatoid

France
Pfizer

Completed

Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

Psoriatic Arthritis

China
Pfizer

Recruiting

Korean Post-marketing Surveillance for Xeljanz XR (XRPMS)

Active Psoriatic Arthritis | Active Ankylosing Spondylitis | Active Moderate to Severe Rheumatoid Arthritis

Korea, Republic of
Fred Hutchinson Cancer Center
AstraZeneca

Recruiting

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Calico Life Sciences LLC
AbbVie

Recruiting

A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

Advanced Solid Tumor Cancer

United States, Korea, Republic of, Israel, Spain, Japan, France
National Cancer Institute (NCI)

Active, not recruiting

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Pfizer

Terminated

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

Plaque Psoriasis

United States, Canada
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Boehringer Ingelheim

Completed

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
Emory University

Terminated

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Yanfeng Hou

Recruiting

Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis

Rheumatoid Arthritis | Therapy

China
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

ALK Fusion-positive Solid or CNS Tumors

United States, Korea, Republic of, China, Spain, Canada, United Kingdom, Australia, Denmark, France, Italy, Germany
Emory University
Eisai Inc.

Terminated

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

Differentiated Thyroid Gland Carcinoma | Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Biliary Tract Cancer | Gemox Chemotherapy

China
Hoffmann-La Roche

Completed

Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, Korea, Republic of
University of Texas Southwestern Medical Center
Pfizer

Recruiting

Tofacitinib in Recurrent GBM Patients

Glioblastoma

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Milton S. Hershey Medical Center; Stanford University and other collaborators

Active, not recruiting

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

Lymphoma | Leukemia | Solid Tumor | Central Nervous System Tumor

United States, Canada
Pfizer

Active, not recruiting

Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

Lung Cancer

Malaysia
Novartis Pharmaceuticals

Available

Managed Access Program (MAP)* to Provide Access to Asciminib for Patients With CML in Chronic Phase

Chronic Myeloid Leukemia
Hunan Province Tumor Hospital

Recruiting

Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China

Search clinical trials for: Cyclin-Dependent Kinase Inhibitor Proteins

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations